Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

The data showed patients who took GLP-1 drugs had a much lower risk of developing cancer than those who took DDP-4s.

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Weight-loss injections could cut the risk of cancer by almost half, research suggests. Researchers analysed the health ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

“More serious but less common risks include pancreatitis, acute kidney injury, retinopathy and thyroid cancer,” says Amidor. Below, Dr. Gould and Amidor offer their tips for safe use of Ozempi ...